Companies /Healthcare

Puma Biotechnology Inc

NASDAQ: PBYI Biotechnology
$7.34
▼ $0.43 (−5.53%) today
Markets closed · 3:55am ET

PBYI at a Glance

Valuation
Market cap
$401.7M
P/E ratio
16.9
Profitability
Revenue (TTM)
$231.8M
Profit margin
10.3%
EPS (TTM)
$0.46
Price
52-week range
$5 – $12
Street target
$6.00

Headquartered in Los Angeles, CA Fiscal year ends December NASDAQ: PBYI pumabiotechnology.com

About Puma Biotechnology

Puma Biotechnology is a biopharmaceutical company that develops and commercializes cancer therapies. Its revenue comes from net product sales of NERLYNX (neratinib), an oral kinase inhibitor it in-licensed in 2011, plus royalties from ex-U.S. commercial partners. NERLYNX is FDA-approved for two U.S. uses: extended adjuvant treatment of early-stage HER2-positive breast cancer after trastuzumab-based therapy (2017), and, with capecitabine, advanced or metastatic HER2-positive breast cancer after two or more prior anti-HER2 regimens (2020). It also holds European Commission marketing authorization (2018). Royalty revenue is pressured by generic versions of NERLYNX in China. The company supports patient access through its Puma Patient Lynx reimbursement program. Its pipeline centers on alisertib, an oral aurora kinase A inhibitor licensed in 2022, being developed for small cell lung cancer and breast cancer in three Phase II trials: ALISCA-Lung1 (monotherapy in extensive-stage SCLC), ALISCA-Breast1 (with endocrine therapy in HR-positive, HER2-negative metastatic breast cancer) and ALISCA-Lung2 (with paclitaxel in advanced SCLC, initiated September 2026). Puma paid off its debt principal in May 2026. Updated

Latest Activity

PBYIPuma Biotechnology
Q3 2026
EPS
$0.15
est $0.12+25.0%
Revenue
$55M
est $58M-4.2%

Generic NERLYNX crossed a market-share threshold in China, forcing a $2.1 million royalty writedown that pushed revenue below expectations even as earnings cleared consensus. Management raised full-year net income guidance to $20 million to $22 million and says delayed ex-US partner shipments land in the fourth quarter.

Quarterly EPS — reported vs estimate

PBYI Coverage

9:15am ET
Health and Healthcare

Why These Breast Cancer Study Results Look So Promising

Puma Biotechnology shares made a handy gain early on Thursday after the company presented updated results from its Phase 2 Summit clinical trial of neratinib at the 2019 San Antonio Breast Cancer…

Chris Lange

Frequently Asked Questions

What does Puma Biotechnology do?

Puma Biotechnology is a biopharmaceutical company that develops and commercializes cancer therapies. Its revenue comes from net product sales of NERLYNX (neratinib), an oral kinase inhibitor it in-licensed in 2011, plus royalties from ex-U.S. commercial partners.

What is the PBYI stock price target?

The Wall Street consensus 12-month price target for PBYI is $6.00.